- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02928016
Effectiveness of Carbohydrate Counting Method With Mixed Meals
October 8, 2016 updated by: Aimilia Papakonstantinou, Agricultural University of Athens
Effectiveness of the Carbohydrate Counting Method on Postprandial Glucose Concentrations After Consumption of Mixed Meals in Adults With Type 1 Diabetes
In a randomized, cross-over designed study, the investigators examined the effectiveness of the carbohydrate counting method after consumption of mixed meals typical of the Greek cuisine with various protein and fat contents in a sample of people with type 1 diabetes (DM1).
The investigators also tried to further explore the effects of additional extra virgin olive oil (11 ml) on the glycemic response.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of 20 adults with type 1 diabetes on intensive insulin therapy consumed three mixed meals at noon between 1200 and 1300 hours, with and without the addition of 11 ml extra virgin oil, in random order.
One week before entering the study, participants kept a detailed 7-day weighed food record with fingerprick blood glucose measurements pre-and-2hour post-meals for calculation of their carbohydrate (g) to insulin (units) ratio.
Moreover, the individual correction factor was calculated.
Thereafter, insulin requirements for the test meals were calculated based on the carbohydrate content of each dish and according to the personalised carbohydrate to insulin ratio.
Postprandial glycemia was measured in capillary blood glucose samples at 30min intervals over 195min.
For 24hr before each testing session, participants were asked to refrain from the consumption of alcohol and to maintain their usual physical activity pattern.
On the day of testing, subjects were asked to consume their usual breakfast and abstain from food for at least 2 hours before their appointment.
If blood glucose was >7.2 mmol/l at 1200, insulin was administered based on the individualised correction factor.
If blood glucose was >10 mmol/l at the beginning of the testing session, insulin was administered to correct it and the subject was asked to return on another day.
if hypoglycaemia occurred (defined as blood glucose level <3.8 mmol/l), the test session was stopped, the event was recorded and the patient treated appropriately.
The on target 2hour postprandial blood glucose level was set between 3.9 and 10 mmol/l.
Anthropometric measurements (body weight, waist and hip circumferences) were performed at every visit.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with type 1 diabetes
- Intensive insulin therapy
- HbA1c < 10%
- >2 years with diabetes
Exclusion Criteria:
- Food allergies
- Diabetic neuropathy
- Kidney disease
- Hematological disturbances
- Liver disease
- Uncontrolled hypo- or hyperthyroidism
- Arrhythmia
- Heart disease
- Cancer
- Serious mental illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mixed meal 1
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes.
No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes).
Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
|
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives.
The meal provided 794 kcal and contained approximately 500 kcal from protein and fat.
Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
|
Experimental: Mixed meal 2
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes.
No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes).
Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
|
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat.
Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
|
Experimental: Mixed meal 3
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes.
No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes).
Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
|
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives.
The meal provided 502 kcal and contained approximately 300 kcal from protein and fat.
Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
|
Experimental: Mixed meal 4
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes.
No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes).
Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
|
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil.
The meal provided 893 kcal and contained approximately 600 kcal from protein and fat.
Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
|
Experimental: Mixed meal 5
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes.
No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes).
Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
|
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil.
The meal provided 497 kcal and contained approximately 300 kcal from protein and fat.
Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
|
Experimental: Mixed meal 6
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes.
No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes).
Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
|
20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil.
The meal provided 601 kcal and contained approximately 400 kcal from protein and fat.
Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Capillary blood glucose
Time Frame: 195 minutes
|
Clinically useful change in capillary blood glucose, defined as the restoration of glucose within normal limits during the first two hours and until the end of the trial
|
195 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
October 6, 2016
First Submitted That Met QC Criteria
October 6, 2016
First Posted (Estimate)
October 7, 2016
Study Record Updates
Last Update Posted (Estimate)
October 11, 2016
Last Update Submitted That Met QC Criteria
October 8, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRBD 11th Session 6/4/2014 NHA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Mixed meal 1
-
National Institute of Diabetes and Digestive and...Not yet recruitingObesity | Healthy VolunteerUnited States
-
Harokopio UniversityCompletedDiabetes Mellitus, Type 2Greece
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
University of VirginiaNational Center for Advancing Translational Sciences (NCATS)Active, not recruitingType 1 Diabetes | Hyperglycemia, PostprandialUnited States
-
ETH ZurichUniversity Hospital, Basel, SwitzerlandRecruiting
-
University of TorontoCompleted
-
Azienda Ospedaliera Universitaria Integrata VeronaUniversita di Verona; European Foundation for the Study of DiabetesUnknownType 1 Diabetes MellitusItaly
-
Mayo ClinicCompleted
-
Icahn School of Medicine at Mount SinaiCompletedType 1 Diabetes MellitusUnited States
-
Maastricht University Medical CenterCompleted